SCOTUS Temporarily Restores Access to Mifepristone via Telehealth, Mail, and Pharmacies

The Supreme Court of the United States (SCOTUS) has restored broad access to mifepristone (Mifeprex; Danco Laboratories), temporarily blocking a ruling that would prevent patients from receiving the pill through the mail and at the pharmacy without a visit to the doctor.¹

According to The New York Times, Justice Samuel A. Alito Jr paused a lower-court ruling from Friday, May 1, 2026, that prevented providers from prescribing mifepristone via telehealth and shipping it to patients, an action that sparked confusion among health care providers and patients.^2,3 His order imposes a pause until at least May 11, and requests that parties file briefs by Thursday, May 7, before the court will determine how to proceed.

What Is Mifepristone?

Mifepristone, which was initially approved by the FDA in 2000, is indicated with misoprostol for the medical termination of a pregnancy that is at less than 70 days of gestation. The regimen requires patients 17 years or older to take a single 200-mg oral dose of mifepristone, followed by 4 oral doses of misoprostol (200 µg) administered 24 to 48 hours after the mifepristone. It halts the supply of hormones that maintain the interior of the uterus; without these hormones, the uterus cannot continue to support the pregnancy and expels the contents within the organ.³

In a misoprostol-alone abortion, patients begin the process with misoprostol, using the same amount as in the 2-drug regimen. They take another dose of misoprostol again 3 hours after, which causes the uterus to contract. This is repeated 3 to 4 times until the pregnancy passes, which may take 9 to 12 hours. NPR reports that, although a misoprostol-only regimen is as safe as the 2-medication counterpart, it may cause more adverse events, such as nausea, vomiting, and diarrhea, as well as a longer duration of cramping and bleeding.⁴

Mifepristone can also be used to control high blood glucose caused by high cortisol levels in the blood in patients with Cushing syndrome who also have type 2 diabetes and have either failed surgery or cannot have it.³

Although it is temporary, the block made by SCOTUS is significant, given that the majority of abortions in the US are obtained through the combination regimen of mifepristone and misoprostol. The availability of those drugs has somewhat diminished the impact of abortion bans that certain states have sought to enforce since a 2022 SCOTUS ruling that overturned Roe v Wade. Other states have enacted laws to legally protect those who prescribe the drugs via telehealth to patients living in states with bans or restrictions.¹

What Do Pharmacists Need to Know?

The FDA assures that mifepristone is safe to use as indicated and directed, provided it is used consistently with the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The Mifepristone REMS program is intended to mitigate the risk of serious complications that are associated with mifepristone when used for medical termination of pregnancy through 10 weeks’ gestation by, among other things, requiring that prescribers have the necessary qualifications to assess whether patients are appropriate candidates for the drug and to provide necessary intervention in case of complications (or have made plans to provide such care through others), ensuring that mifepristone is only dispensed by certified pharmacies or by or under the supervision of certified prescribers, and requiring that patients be informed of the risks of the treatment regimen.⁵

This program ensures the safe use of mifepristone and any FDA-approved generic versions. The following requirements—among others—are a part of the program⁵:

• Mifepristone must be prescribed by a health care provider who meets certain qualifications and is certified under the mifepristone REMS program.
• Health care providers must complete a prescriber agreement form in order to become certified to prescribe mifepristone.
• The patient agreement form must be reviewed with and signed by the patient and the health care provider, and the risks of the mifepristone treatment regimen must be fully explained to the patient before prescribing mifepristone.
• The patient must be provided with a copy of the patient agreement form and the mifepristone medication guide (FDA-approved information for patients).
• Mifepristone may only be dispensed by or under the supervision of a certified prescriber, or by a certified pharmacy on a prescription issued by a certified prescriber.
• To become certified to dispense mifepristone, pharmacies must complete a pharmacy agreement form.
• Certified pharmacies must be able to ship mifepristone using a shipping service that provides tracking information.
• Certified pharmacies must ensure mifepristone is dispensed to the patient in a timely manner.

The pause, although temporary, emphasizes the ongoing legal and regulatory uncertainty surrounding access to mifepristone and the broader landscape of reproductive health care within the US. For pharmacists, staying informed on evolving policies, REMS requirements, and state-specific regulations is essential to ensuring patients receive safe and effective care. As access pathways continue to shift—particularly through telehealth and certified pharmacy dispensing—pharmacists remain vital in maintaining continuity of care, providing accurate counseling, and supporting patients in a complex, changing treatment landscape.

REFERENCES

1. Sherman M, Mulvihill G. Supreme Court restores access to abortion pill mifepristone through telehealth, mail and pharmacies. Associated Press. May 4, 2026. Accessed May 4, 2026. https://apnews.com/article/abortion-pills-mifepristone-supreme-court-louisiana-0533e83d67148fdfec53b1d0d30c1e8a

2. Marimow AE. Supreme Court temporarily restores access to abortion pill by mail. New York Times. May 4, 2026. Accessed May 4, 2026. https://www.nytimes.com/2026/05/04/us/politics/supreme-court-abortion-pill.html

3. McGovern G. FDA approves generic mifepristone tablets for abortion. Pharmacy Times. October 3, 2025. Accessed May 4, 2026. https://www.pharmacytimes.com/view/fda-approves-generic-mifepristone-tablets-for-abortion

4. Gordon M, Simmons-Duffin S, Webber D. Here's how medication abortion works with just one drug. NPR. May 4, 2026. Accessed May 4, 2026. https://www.npr.org/2026/05/04/g-s1-119947/telehealth-abortion-mifepristone-misoprostol

5. Questions and answers on mifepristone for medical termination of pregnancy through ten weeks gestation. FDA. Updated April 8, 2026. Accessed May 4, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation